5,039 results match your criteria Cephalalgia[Journal]


Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I] galcanezumab in male rats.

Cephalalgia 2019 Apr 19:333102419844711. Epub 2019 Apr 19.

1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.

Objective: The objective of this investigation was to examine the distribution of galcanezumab and a control immunoglobulin 4 antibody containing the same constant regions as galcanezumab, into peripheral and central tissues.

Methods: Galcanezumab and a control immunoglobulin 4 antibody were radioiodinated with Iodine-125 to specific activities of 0.11 mCi/mg and 0. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102419844711
Publisher Site
http://dx.doi.org/10.1177/0333102419844711DOI Listing
April 2019
1 Read

The diagnostic accuracy of headache measurement instruments: A systematic review and meta-analysis focusing on headaches associated with musculoskeletal symptoms.

Cephalalgia 2019 Apr 18:333102419840777. Epub 2019 Apr 18.

6 University Medical Center Utrecht, Utrecht University, Department of Oral-Maxillofacial Surgery and Special Dental Care, Utrecht, the Netherlands.

Aim: To systematically review the available literature on the diagnostic accuracy of questionnaires and measurement instruments for headaches associated with musculoskeletal symptoms.

Design: Articles were eligible for inclusion when the diagnostic accuracy (sensitivity/specificity) was established for measurement instruments for headaches associated with musculoskeletal symptoms in an adult population. The databases searched were PubMed (1966-2018), Cochrane (1898-2018) and Cinahl (1988-2018). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419840777DOI Listing

Board Walk - April 2019.

Authors:
Stefan Evers

Cephalalgia 2019 Apr;39(5):678-680

University of Münster and Krankenhaus Lindenbrunn, Germany Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419833845DOI Listing

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Cephalalgia 2019 Apr 13:333102419835459. Epub 2019 Apr 13.

7 Amgen Inc., Thousand Oaks, CA, USA.

Background: Erenumab was effective and well tolerated in a pivotal clinical trial of episodic migraine that included subjects both naïve to, and those who had failed, previous preventives. Here we evaluated the efficacy and safety of erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s): ≥1 or ≥2 prior failed migraine preventive categories, and in patients who had never failed.

Methods: Prespecified subgroup analyses evaluated change from baseline to months 4-6 (the primary endpoint of the blinded study phase) in monthly migraine days, achievement of ≥50% and ≥75% reduction in monthly migraine days, and change from baseline in acute migraine-specific medication days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419835459DOI Listing
April 2019
1 Read

Cyclic vomiting syndrome and benign paroxysmal torticollis are associated with a high risk of developing primary headache: A longitudinal study.

Cephalalgia 2019 Apr 13:333102419844542. Epub 2019 Apr 13.

1 Headache Center, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Background And Aim: Episodic syndromes that may be associated with migraine are a group of disorders affecting patients with migraine or with an increased risk of presenting it, and likely represent an early life expression of migraine. Cyclic vomiting syndrome and benign paroxysmal torticollis are well characterized and represent a frequent cause of request for specialist consultations. The aim of this study is to longitudinally assess the rate of headache in patients presenting with cyclic vomiting syndrome and benign paroxysmal torticollis during infancy, and to define the main clinical features of the disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419844542DOI Listing
April 2019
2 Reads

Headaches and sleep problems in US adolescents: Findings from the National Comorbidity Survey - Adolescent Supplement (NCS-A).

Cephalalgia 2019 Apr 13:333102419835466. Epub 2019 Apr 13.

1 Genetic Epidemiology Branch, National Institute of Mental Health, Bethesda, MD, USA.

Background: There is limited research on the association of sleep problems with International Classification of Headache Disorders (ICHD-II)-defined headache subtypes in youth, particularly from community-based samples. This cross-sectional study examines the associations of sleep patterns, symptoms and disorders with specific headache subtypes among adolescents from the general population of the United States.

Methods: The sample includes 10,123 adolescents in the National Comorbidity Survey - Adolescent Supplement, a face-to-face survey of adolescents aged 13-18 years in the continental USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419835466DOI Listing
April 2019
2 Reads

Board Walk - April 2019.

Cephalalgia 2019 Apr;39(4):569-570

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419834487DOI Listing

Age- and sex-specific first health care use for migraine in 2016 in children and adolescents from prospectively collected health insurance data in Germany.

Cephalalgia 2019 Apr 11:333102419844543. Epub 2019 Apr 11.

2 Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany.

Background: Migraine in children and adolescents is associated with significant disability and a high risk of persistence into adulthood.

Objective: Data on migraine incidence in children and adolescents are few and relatively coarse. To tailor interventions starting shortly after disease onset, detailed information on age- and sex-specific incidence of migraine in children and adolescents is needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419844543DOI Listing

Association of migraine with calcification in major vessel beds: The Rotterdam Study.

Cephalalgia 2019 Apr 8:333102419843148. Epub 2019 Apr 8.

1 Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Background: To explore the role of large-artery atherosclerosis in migraine, we investigated the association between migraine and arterial calcification in different intracranial and extracranial vessels.

Methods: 1856 participants were included, mean age (standard deviation) 67.4 (5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419843148DOI Listing
April 2019
3 Reads

Prevalence of headache attributed to aeroplane travel in headache outpatient populations: An Italian multicentric survey.

Cephalalgia 2019 Apr 8:333102419843676. Epub 2019 Apr 8.

2 Headache Centre, Department of Neurosciences, University of Padua, Padua, Italy.

Background: To assess the prevalence of headache attributed to aeroplane travel (AH) in patients referred to Italian Headache Centres.

Material And Method: 869 consecutive patients visiting six Italian headache centres during a 6 month-period (October 2013 to March 2014) were enrolled in the survey. Among them, 136 (15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419843676DOI Listing
April 2019
2 Reads

Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition.

Cephalalgia 2019 Apr 4:333102419842188. Epub 2019 Apr 4.

4 Headache Science Center, IRCCS C. Mondino Foundation, Pavia, Italy.

Background: Because the results of clinical trials of investigational treatments influence regulatory policy, prescribing patterns, and use in clinical practice, high quality trials are an essential component of the evidence base for migraine. The International Headache Society has published guidelines for clinical trials in adults with migraine since 1991. With multiple issues specific to children and adolescents with migraine, as well as the emergence of novel trial designs and advances in pharmaceuticals, biologics, devices, and behavioural interventions, there is a need for guidance focusing on issues specific to the conduct of clinical trials in children and adolescents with migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419842188DOI Listing
April 2019
3 Reads

Characterization and predictive mechanisms of experimentally induced tension-type headache.

Cephalalgia 2019 Mar 28:333102419840779. Epub 2019 Mar 28.

1 Section of Orofacial Pain and Jaw Function, Department of Dentistry, Aarhus University, Aarhus, Denmark.

Objective: Studies have shown it is possible to elicit a tension-type headache episode in 15 to 30% of healthy individuals following a tooth-clenching or stress-inducing task. Despite this, no studies have attempted to understand why some healthy individuals develop a headache episode while others do not.

Methods: The present randomized, single-blind, controlled study recruited 60 healthy participants who participated in a 30-minute tooth-clenching task and 10 participants who participated in a control task. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419840779DOI Listing

Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions.

Cephalalgia 2019 Mar 28:333102419839967. Epub 2019 Mar 28.

1 Neurological Clinic, Department of Medicine, Hospital Santa Maria della Misericordia, University of Perugia, Perugia, Italy.

Introduction: Familial hemiplegic migraine 2 is a pathology linked to mutation of the ATP1A2 gene producing loss of function of the α2 Na/K-ATPase (NKA). W887R/+ knock-in (KI) mice are used to model the familial hemiplegic migraine 2 condition and are characterized by 50% reduced NKA expression in the brain and reduced rate of K and glutamate clearance by astrocytes. These alterations might, in turn, produce synaptic changes in synaptic transmission and plasticity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839967DOI Listing

Current understanding of cortical structure and function in migraine.

Cephalalgia 2019 Mar 28:333102419840643. Epub 2019 Mar 28.

5 Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Objective: To review and discuss the literature on the role of cortical structure and function in migraine.

Discussion: Structural and functional findings suggest that changes in cortical morphology and function contribute to migraine susceptibility by modulating dynamic interactions across cortical and subcortical networks. The involvement of the cortex in migraine is well established for the aura phase with the underlying phenomenon of cortical spreading depolarization, while increasing evidence suggests an important role for the cortex in perception of head pain and associated sensations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419840643DOI Listing

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.

Cephalalgia 2019 Mar 27:333102419840780. Epub 2019 Mar 27.

Eli Lilly and Company, Indianapolis, IN, USA.

Purpose: To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies.

Overview: Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an antibody that binds to the ligand calcitonin gene-related peptide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419840780DOI Listing

Genetics of cluster headache.

Cephalalgia 2019 Mar 27:333102418815503. Epub 2019 Mar 27.

1 Xenon Pharmaceuticals Inc, Burnaby, Canada.

Background: Cluster headache is the most severe primary headache disorder. A genetic basis has long been suggested by family and twin studies; however, little is understood about the genetic variants that contribute to cluster headache susceptibility.

Methods: We conducted a literature search of the MEDLINE database using the PubMed search engine to identify all human genetic studies for cluster headache. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418815503DOI Listing
March 2019
1 Read

Differences in fibertract profiles between patients with migraine and those with persistent post-traumatic headache.

Cephalalgia 2019 Mar 26:333102418815650. Epub 2019 Mar 26.

1 Mayo Clinic Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.

Objectives: Often, persistent post-traumatic headache and migraine are phenotypically similar. However, the similarities and differences in the neuropathological underpinnings of persistent post-traumatic headache and migraine require further understanding. We used diffusion tensor imaging (DTI) and a novel method for detecting subtle changes in fibertract integrity by measuring node-by-node parameters along each tract to compare fibertract profiles between those with migraine and those with persistent post-traumatic headache, and compared both cohorts to a group of controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418815650DOI Listing
March 2019
1 Read

The spectrum of cluster headache: A case report of 4600 attacks.

Cephalalgia 2019 Mar 26:333102419833081. Epub 2019 Mar 26.

1 Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Introduction: Knowledge of the clinical features of cluster headache is mainly based on retrospective and cross-sectional studies. Here, we present a case of a chronic cluster headache patient who prospectively recorded timing and clinical features of all attacks for 6 years, aiming to describe the clinical spectrum and timing of cluster headache symptoms experienced and to identify daily and/or seasonal rhythmicity.

Methods: Registration of attack timing, duration, associated symptoms and severity was done prospectively on a smartphone application. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102419833081
Publisher Site
http://dx.doi.org/10.1177/0333102419833081DOI Listing
March 2019
1 Read

Migraine classification using somatosensory evoked potentials.

Cephalalgia 2019 Mar 26:333102419839975. Epub 2019 Mar 26.

1 School of Electrical and Computer Engineering, Cornell University, Ithaca, NY, USA.

Objective: The automatic detection of migraine states using electrophysiological recordings may play a key role in migraine diagnosis and early treatment. Migraineurs are characterized by a deficit of habituation in cortical information processing, causing abnormal changes of somatosensory evoked potentials. Here, we propose a machine learning approach to utilize somatosensory evoked potential-based biomarkers for migraine classification in a noninvasive setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839975DOI Listing

Ventral tegmental area deep brain stimulation for chronic cluster headache: Effects on cognition, mood, pain report behaviour and quality of life.

Cephalalgia 2019 Mar 21:333102419839957. Epub 2019 Mar 21.

1 Unit of Functional Neurosurgery, Sobell Department of Motor Neuroscience and Movement Disorders, UCL Queen Square Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.

Background: Deep brain stimulation in the ventral tegmental area (VTA-DBS) has provided remarkable therapeutic benefits in decreasing headache frequency and severity in patients with medically refractory chronic cluster headache (CH). However, to date the effects of VTA-DBS on cognition, mood and quality of life have not been examined in detail.

Methods: The aim of the present study was to do so in a case series of 18 consecutive patients with cluster headache who underwent implantation of deep brain stimulation electrodes in the ventral tegmental area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839957DOI Listing
March 2019
5 Reads

Dr James Lance, Professor of Neurology in Sydney, Australia, died on 20 February 2019, age 92.

Cephalalgia 2019 Apr 21;39(5):681-682. Epub 2019 Mar 21.

3 King's College London, London, UK Corresponding author: Stefan Evers, Lindenbrunn Hospital, 31863 Coppenbrügge, Germany. Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419840639DOI Listing
April 2019
1 Read

A prospective study of headache and neuropeptides in patients with pituitary adenomas.

Cephalalgia 2019 Mar 21:333102419839963. Epub 2019 Mar 21.

1 Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Objective: To evaluate clinical criteria for headache associated with pituitary adenoma (HaPA) in the International Classification of Headache Disorders (ICHD) 3rd edition version criteria and further determine whether elevations of plasma calcitonin gene-related peptide and pituitary adenylate cyclase-activating peptide 1-38 (PACAP1-38) concentration contribute to HaPA.

Methods: Demographic and clinical features of consecutive patients with pituitary adenoma were recorded. Plasma calcitonin gene-related peptide and PACAP1-38 concentrations in pituitary adenoma patients within 72 h pre- and post-operation were measured. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839963DOI Listing

Deep brain stimulation of chronic cluster headaches: Posterior hypothalamus, ventral tegmentum and beyond.

Cephalalgia 2019 Mar 21:333102419839992. Epub 2019 Mar 21.

3 Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.

Objective: We present long-term follow-up results and analysis of stimulation sites of a prospective cohort study of six patients with chronic cluster headaches undergoing deep brain stimulation of the ipsilateral posterior hypothalamic region.

Methods: The primary endpoint was the postoperative change in the composite headache severity score "headache load" after 12 months of chronic stimulation. Secondary endpoints were the changes in headache attack frequency, headache attack duration and headache intensity, quality of life measures at 12, 24, and 48 months following surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839992DOI Listing

Epicrania Fugax as the presenting symptom of a cerebellar abscess.

Cephalalgia 2019 Mar 20:333102419839793. Epub 2019 Mar 20.

1 Headache Unit, University Hospital of Valladolid, Valladolid, Spain.

Background: Epicrania fugax is included in the appendix of the International Classification of Headache Disorders and is characterized as recurrent brief attacks of linear or zigzag pain moving across the cranial surface, commencing and terminating in the distribution of different nerves. We present a new case of epicrania fugax in which the headache was the presenting symptom of a cerebellar abscess.

Case Report: We present a 58-year-old woman with prior history of Chiari I malformation who underwent suboccipital craniectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839793DOI Listing
March 2019
4 Reads

The prevalence of headache in German pupils of different ages and school types.

Cephalalgia 2019 Mar 18:333102419837156. Epub 2019 Mar 18.

1 Pain Center, University Hospital and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.

Background/objective: Headache in pupils is underestimated and has a negative impact on learning and life. The aim of this study was to investigate headache prevalence and its collateral effects, in pupils of different ages and school types in a German city.

Methods: Anonymized questionnaires were distributed to 5419 pupils attending primary and secondary schools. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419837156DOI Listing
March 2019
2 Reads

Short-lasting retroorbital pain attacks as a form of ictal epileptic headache: Case report.

Cephalalgia 2019 Mar 16:333102419839792. Epub 2019 Mar 16.

1 Department of Clinical Neurophysiology, King's College Hospital, London, UK.

Background And Objectives: Ictal epileptic headache is a rare form of painful seizure, habitually consisting of migrainous or tension-type headache. We describe a case of a patient with short-lasting, severe retroorbital pain attacks caused by frontal lobe epilepsy.

Case Report: A 25-year-old male patient presented with recurrent attacks of paroxysmal, short-lasting, excruciating left periorbital and facial pain mainly occurring from sleep. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839792DOI Listing
March 2019
1 Read

Does insomnia modify the association between C-reactive protein and migraine? The Tromsø Study 2015-2016.

Cephalalgia 2019 Mar 12:333102418825370. Epub 2019 Mar 12.

1 Department of Neuroscience and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.

Background: The relationship between high sensitivity C-reactive protein and migraine is unclear. The aim of this cross-sectional population-based study was to investigate the association between high sensitivity C-reactive protein and types of headache, and to evaluate the impact of insomnia on this association.

Methods: A total of 20,486 (63%) out of 32,591 invited, aged ≥40 years or older, participated in the seventh wave of the Tromsø study conducted in 2015-2016 and had valid information on headache, insomnia and high sensitivity C-reactive protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418825370DOI Listing

Field testing the diagnostic criteria of cluster headache in the third edition of the International Classification of Headache Disorders: A cross-sectional multicentre study.

Cephalalgia 2019 Mar 11:333102419837159. Epub 2019 Mar 11.

17 Department of Neurology, Severance Hospital, Yonsei University School of Medicine, Seoul, Korea.

Background: *These authors are shared first authors. The recently published third edition of the International Classification of Headache Disorders (ICHD-3) revised the criteria for accompanying symptoms of cluster headache (CH) and the remission period of chronic cluster headache (CCH). This study aimed at testing the validity of the ICHD-3 criteria for CH by using data from the Korean Cluster Headache Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419837159DOI Listing
March 2019
3 Reads

The vast potential of claims data to reduce undiagnosed chronic migraine.

Cephalalgia 2019 Apr 9;39(4):463-464. Epub 2019 Mar 9.

Massachusetts General Hospital, Harvard Medical School, Anesthesia, Critical Care and Pain Medicine, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419836479DOI Listing
April 2019
2 Reads

Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients.

Cephalalgia 2019 Apr 9;39(4):465-476. Epub 2019 Mar 9.

8 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.

Objective: To develop a claims-based algorithm to identify undiagnosed chronic migraine among patients enrolled in a healthcare system.

Methods: An observational study using claims and patient survey data was conducted in a large medical group. Eligible patients had an International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10) migraine diagnosis, without a chronic migraine diagnosis, in the 12 months before screening and did not have a migraine-related onabotulinumtoxinA claim in the 12 months before enrollment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418825373DOI Listing
April 2019
2 Reads

Calcitonin-gene related peptide and disease activity in cluster headache.

Cephalalgia 2019 Apr 9;39(5):575-584. Epub 2019 Mar 9.

1 Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Objective: To investigate the role of calcitonin gene-related peptide, pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide in cluster headache, we measured these vasoactive peptides interictally and during experimentally induced cluster headache attacks.

Methods: We included patients with episodic cluster headache in an active phase (n = 9), episodic cluster headache patients in remission (n = 9) and patients with chronic cluster headache (n = 13). Cluster headache attacks were induced by infusion of calcitonin gene-related peptide (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419837154DOI Listing
April 2019
1 Read

Functional connectivity of hypothalamus in chronic migraine with medication overuse.

Cephalalgia 2019 Mar 5:333102419833087. Epub 2019 Mar 5.

1 Department of Neurology, University Hospital of Toulouse, Toulouse, France.

Objective: To investigate the functional connectivity of the hypothalamus in chronic migraine compared to interictal episodic migraine in order to improve our understanding of migraine chronification.

Methods: Using task-free fMRI and ROI-to-ROI analysis, we compared anterior hypothalamus intrinsic connectivity with the spinal trigeminal nucleus in patients with chronic migraine (n = 25) to age- and sex-matched patients with episodic migraine in the interictal phase (n = 22). We also conducted a seed-to-voxel analysis with anterior hypothalamus as a seed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419833087DOI Listing

Discovery of CGRP in relation to migraine.

Cephalalgia 2019 Mar;39(3):331-332

2 Headache Group - NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418779544DOI Listing

Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine.

Cephalalgia 2019 Feb 28:333102419835465. Epub 2019 Feb 28.

2 Center for Observational Research, Amgen, Thousand Oaks, CA, USA.

Objectives: To describe long-term treatment patterns in migraine patients initiating prophylactic therapy and to evaluate acute medication use and adverse events associated with opioids.

Methods: This study used the 2005-2014 IBM MarketScan® databases to evaluate migraine patients initiating prophylactic medication. Outcome measures included persistence with prophylactic migraine medications over 2-5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419835465DOI Listing
February 2019
3 Reads

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Cephalalgia 2019 Feb 26:333102419828967. Epub 2019 Feb 26.

15 Department of Health Sciences Research, Mayo Clinic Rochester, MN, USA.

The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. Scientific and clinical developments in headache medicine led to second and third editions in 2000 and 2012, respectively. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102419828967
Publisher Site
http://dx.doi.org/10.1177/0333102419828967DOI Listing
February 2019
12 Reads

Leptin, adiponectin, and resistin blood adipokine levels in migraineurs: Systematic reviews and meta-analyses.

Cephalalgia 2019 Feb 24:333102418807182. Epub 2019 Feb 24.

1 Department of Clinical Biochemistry, Faculty of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran.

Introduction: Migraine comorbidity with obesity is not new and studies have focused on how adipose tissue-derived substances such as adipokines might be involved in the migraine pathophysiology. Quantification of the nature and magnitude of the association between each adipokine including leptin, adiponectin and resistin with migraine pathophysiology is the objective of the current study.

Methods: Using systematic reviews and meta-analyses and standardized mean difference as effect size, the levels of three adipokines, leptin, adiponectin and resistin, have been investigated in migraineur subjects in the case-control studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418807182DOI Listing
February 2019
4.891 Impact Factor

Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.

Cephalalgia 2019 Feb 21:333102419829007. Epub 2019 Feb 21.

Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Aim: To systematically evaluate the safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies from the results of randomized controlled trials.

Methods: Online databases were searched on calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine. Overall withdrawal, withdrawal due to adverse events, adverse events, serious adverse events and specific adverse events were extracted from the included studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419829007DOI Listing
February 2019

Assessing evidence-based medicine and opioid/barbiturate as first-line acute treatment of pediatric migraine and primary headache: A retrospective observational study of health systems data.

Cephalalgia 2019 Feb 20:333102419833080. Epub 2019 Feb 20.

5 Mercy Research, Chesterfield, MO, USA.

Objectives: To evaluate providers' use and predictors of evidence-based medicine or opioid/barbiturate as first-line acute treatment for children's initial presentation of acute migraine or primary headache.

Methods: This retrospective, observational study utilized patient (children ages 6-17) and provider/encounter characteristics extracted from the patient's Electronic Health Record from 2008-2014 during an initial encounter for migraine or primary headache. The primary outcome was provider evidence-based medicine utilization; overall prescriptions and opioid/barbiturate prescriptions were also evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419833080DOI Listing
February 2019
5 Reads

Increased cerebral responses to salient transitions between alternating stimuli in chronic migraine with medication overuse headache and during migraine attacks.

Cephalalgia 2019 Feb 20:333102418825359. Epub 2019 Feb 20.

2 Headache Research Unit, Department of Neurology, CHR Citadelle, University of Liège, Liège, Belgium.

Introduction: In a previous study exploring central pain modulation with heterotopic stimuli in healthy volunteers, we found that transitions between sustained noxious and innocuous thermal stimulations on the foot activated the "salience matrix". Knowing that central sensory processing is abnormal in migraine, we searched in the present study for possible abnormalities of these salient transitional responses in different forms of migraine and at different time points of the migraine cycle.

Methods: Participants of both sexes, mostly females, took part in a conditioned pain modulation experiment: Migraineurs between (n = 14) and during attacks (n = 5), chronic migraine patients with medication overuse headache (n = 7) and healthy volunteers (n = 24). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418825359DOI Listing
February 2019

Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon.

Cephalalgia 2019 Feb 20:333102419833076. Epub 2019 Feb 20.

4 Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

Background: Non-invasive stimulation of the vagus nerve has been proposed as a new neuromodulation therapy to treat primary headache disorders, as the vagus nerve is hypothesized to modulate the headache pain pathways in the brain. Vagus nerve stimulation can be performed by placing an electrode on the ear to stimulate the tragus nerve, which contains about 1% of the vagus fibers. Non-invasive vagus nerve stimulation (nVNS) conventionally refers to stimulation of the cervical branch of the vagus nerve, which is made up entirely of vagal nerve fibers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419833076DOI Listing
February 2019
2 Reads

The prevalence of primary headache disorders in the adult population of Estonia.

Cephalalgia 2019 Feb 11:333102419829909. Epub 2019 Feb 11.

1 Neurology Clinic, Tartu University Hospital, Tartu, Estonia.

Objective: To estimate the one-year prevalence of primary headaches, most importantly migraine and tension type headache, but also other primary headaches, in Estonia.

Methods: A population-based random sample of 2162 subjects in Tartu City and Tartu County were interviewed by telephone or face to face using a previously validated questionnaire.

Results: Of the 2162 contacted participants, 1215 (56%) fully completed the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419829909DOI Listing
February 2019
6 Reads

Age related metabolic modifications in the migraine brain.

Cephalalgia 2019 Feb 11:333102419828984. Epub 2019 Feb 11.

5 Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Neurology, Brussels, Belgium.

Purpose: The aim of this study was to evaluate the possibility that migraine patients exhibit specific age-related metabolic changes in the brain, which occur regardless of disease duration or the frequency of attacks.

Methods: We analysed the relation between brain glucose (F-fluorodeoxyglucose) uptake and age in healthy volunteers (n = 20) and episodic migraine patients (n = 19). In the latter, we additionally compared the correlation between F-fluorodeoxyglucose uptake and disease duration and monthly migraine days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419828984DOI Listing
February 2019

Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study.

Cephalalgia 2019 Feb 7:333102418825346. Epub 2019 Feb 7.

4 Department of Neurology, Albert Einstein College of Medicine, New York, NY, USA.

Background: Cutaneous allodynia is a common clinical feature of migraine that has been associated with reduced efficacy of acute migraine treatments and an increased risk of disease progression.

Objective: Identify factors associated with allodynia in a sample of adults with migraine.

Methods: An online survey panel was used to identify adults with migraine who averaged at least 1 monthly headache day over the previous 3 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418825346DOI Listing
February 2019
4.891 Impact Factor

Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial.

Cephalalgia 2019 Feb 7:333102419828994. Epub 2019 Feb 7.

Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.

Background: Medication-overuse headache leads to high disability and decreased quality of life, and the best approach for withdrawal has been debated.

Aim: To compare change in disability and quality of life between two withdrawal programs.

Methods: We randomized medication-overuse headache patients to program A (two months without acute analgesics or migraine medications) or program B (two months with acute medications restricted to two days/week) in a prospective, outpatient study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419828994DOI Listing
February 2019
1 Read

Parental migraine in relation to migraine in offspring: Family linkage analyses from the HUNT Study.

Cephalalgia 2019 Feb 2:333102419828989. Epub 2019 Feb 2.

2 Research and Communication Unit for Musculoskeletal Health, Division of Clinical Neuroscience, Oslo University Hospital, Ullevål, Oslo, Norway.

Background: Migraine is known to run in families. While some clinical studies have indicated that migraine is disproportionally transmitted through the maternal line, this has not been examined in a population-based setting.

Methods: We utilized a large, population-based cohort study from Norway, the HUNT Study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419828989DOI Listing
February 2019

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.

Authors:
David W Dodick

Cephalalgia 2019 Mar 19;39(3):445-458. Epub 2019 Jan 19.

Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA.

Background: Monoclonal antibodies that target calcitonin gene-related peptide or the canonical calcitonin gene-related peptide receptor have emerged as effective and well tolerated for the preventive treatment of migraine. These large molecules appear ideally suited for migraine prevention. They have an extended biological half-life, are administered either monthly or quarterly either by subcutaneous injection or intravenous infusion, require minimal or no dose-titration and have the potential for a rapid onset of effect compared to conventional oral preventive drugs. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102418821662
Publisher Site
http://dx.doi.org/10.1177/0333102418821662DOI Listing
March 2019
15 Reads

The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: A randomized double-blind controlled trial.

Cephalalgia 2019 Jan 8:333102418820102. Epub 2019 Jan 8.

1 Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: The current study was designed to assess the effect of supplementation with a 14-strain probiotic mixture on episodic and chronic migraine characteristics.

Methods: Forty episodic and 39 chronic migraine patients who completed this randomized double-blind controlled trial received two capsules of multispecies probiotic or placebo. The migraine severity was assessed by visual analog scale (VAS). Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102418820102
Publisher Site
http://dx.doi.org/10.1177/0333102418820102DOI Listing
January 2019
17 Reads

Paroxysmal pressing headache: A new short-lasting headache.

Cephalalgia 2019 Jan 6:333102418821671. Epub 2019 Jan 6.

6 Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos, Madrid, Spain.

Introduction: In this report we describe a series of patients with a previously undescribed headache.

Methods: Over a 4-year period, we recruited 14 patients with a distinctive type of head pain of unknown cause that did not meet diagnostic criteria for other primary headaches.

Results: Nine women and five men with a mean age of 49. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418821671DOI Listing
January 2019
3 Reads

The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial.

Cephalalgia 2019 Apr 6;39(5):648-654. Epub 2019 Jan 6.

1 Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Purpose: The present study aimed to determine the effects of combined supplementation of Coenzyme Q10 with L-carnitine on mitochondrial metabolic disorders marker and migraine symptoms among migraine patients.

Methods: A total of 56 men and women, between 20-40 years of age with migraine headache, participated in this randomized, double-blind, placebo-controlled, parallel study. The subjects were randomly assigned to receive either 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine at the same time and/or placebo tablets for 8 weeks. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102418821661
Publisher Site
http://dx.doi.org/10.1177/0333102418821661DOI Listing
April 2019
4 Reads
4.891 Impact Factor

Greater occipital nerve block in migraine prophylaxis: Narrative review.

Cephalalgia 2019 Jan 6:333102418821669. Epub 2019 Jan 6.

5 Ministry of Health Ankara Research and Training Hospital, Algology Clinic, Ankara, Turkey.

Objectives: The importance and popularity of peripheral nerve block procedures have increased in the treatment of migraine. Greater occipital nerve (GON) block is a commonly used peripheral nerve block method, and there are numerous researches on its use in migraine treatment.

Materials And Methods: A search of PubMed for English-language randomized controlled trials (RCT) and open studies on greater occipital nerve block between 1995 and 2018 was performed using greater occipital nerve, headache, and migraine as keywords. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102418821669
Publisher Site
http://dx.doi.org/10.1177/0333102418821669DOI Listing
January 2019
2 Reads